vs

Side-by-side financial comparison of FINANCIAL INSTITUTIONS INC (FISI) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $62.7M, roughly 1.2× FINANCIAL INSTITUTIONS INC). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -2.0%).

The Mizuho Financial Group, Inc. , known from 2000 to 2003 as Mizuho Holdings and abbreviated as MHFG or simply Mizuho, is a Japanese banking holding company headquartered in the Ōtemachi district of Chiyoda, Tokyo, Japan. The group was formed in 2000–2002 by merger of Dai-Ichi Kangyo Bank, Fuji Bank, and Industrial Bank of Japan. The name mizuho (瑞穂) literally means "abundant rice" in Japanese and "harvest" in the figurative sense.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

FISI vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.2× larger
PBYI
$75.5M
$62.7M
FISI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-2.0%
FISI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FISI
FISI
PBYI
PBYI
Revenue
$62.7M
$75.5M
Net Profit
$21.0M
Gross Margin
69.3%
Operating Margin
22.7%
Net Margin
33.5%
Revenue YoY
27.7%
Net Profit YoY
24.3%
EPS (diluted)
$1.04
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FISI
FISI
PBYI
PBYI
Q1 26
$62.7M
Q4 25
$64.1M
$75.5M
Q3 25
$63.8M
$54.5M
Q2 25
$59.7M
$52.4M
Q1 25
$57.2M
$46.0M
Q4 24
$41.6M
$59.1M
Q3 24
$50.1M
$80.5M
Q2 24
$65.2M
$47.1M
Net Profit
FISI
FISI
PBYI
PBYI
Q1 26
$21.0M
Q4 25
$20.0M
Q3 25
$20.5M
$8.8M
Q2 25
$17.5M
$5.9M
Q1 25
$16.9M
$3.0M
Q4 24
$-82.8M
Q3 24
$13.5M
$20.3M
Q2 24
$25.6M
$-4.5M
Gross Margin
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Operating Margin
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
37.4%
22.7%
Q3 25
39.5%
17.6%
Q2 25
36.0%
12.7%
Q1 25
36.0%
8.7%
Q4 24
-276.9%
22.6%
Q3 24
29.0%
27.4%
Q2 24
46.2%
-4.6%
Net Margin
FISI
FISI
PBYI
PBYI
Q1 26
33.5%
Q4 25
38.3%
Q3 25
32.1%
16.2%
Q2 25
29.3%
11.2%
Q1 25
29.5%
6.5%
Q4 24
-198.9%
Q3 24
26.9%
25.2%
Q2 24
39.3%
-9.6%
EPS (diluted)
FISI
FISI
PBYI
PBYI
Q1 26
$1.04
Q4 25
$0.96
$0.26
Q3 25
$0.99
$0.17
Q2 25
$0.85
$0.12
Q1 25
$0.81
$0.06
Q4 24
$-5.32
$0.40
Q3 24
$0.84
$0.41
Q2 24
$1.62
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FISI
FISI
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$85.5M
$97.5M
Total DebtLower is stronger
$114.0M
$22.7M
Stockholders' EquityBook value
$130.3M
Total Assets
$6.3B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FISI
FISI
PBYI
PBYI
Q1 26
$85.5M
Q4 25
$108.8M
$97.5M
Q3 25
$185.9M
$94.4M
Q2 25
$93.0M
$96.0M
Q1 25
$167.4M
$93.2M
Q4 24
$87.3M
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Total Debt
FISI
FISI
PBYI
PBYI
Q1 26
$114.0M
Q4 25
$193.7M
$22.7M
Q3 25
$115.0M
$34.0M
Q2 25
$115.0M
$45.3M
Q1 25
$124.9M
$56.7M
Q4 24
$124.8M
$68.0M
Q3 24
$124.8M
$79.3M
Q2 24
$124.7M
$90.7M
Stockholders' Equity
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
$628.9M
$130.3M
Q3 25
$621.7M
$115.3M
Q2 25
$601.7M
$104.7M
Q1 25
$589.9M
$97.1M
Q4 24
$569.0M
$92.1M
Q3 24
$500.3M
$71.1M
Q2 24
$467.7M
$48.5M
Total Assets
FISI
FISI
PBYI
PBYI
Q1 26
$6.3B
Q4 25
$6.3B
$216.3M
Q3 25
$6.3B
$202.9M
Q2 25
$6.1B
$194.9M
Q1 25
$6.3B
$196.2M
Q4 24
$6.1B
$213.3M
Q3 24
$6.2B
$220.7M
Q2 24
$6.1B
$205.0M
Debt / Equity
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
0.31×
0.17×
Q3 25
0.18×
0.30×
Q2 25
0.19×
0.43×
Q1 25
0.21×
0.58×
Q4 24
0.22×
0.74×
Q3 24
0.25×
1.12×
Q2 24
0.27×
1.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FISI
FISI
PBYI
PBYI
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
$18.8M
$14.4M
Q3 25
$-6.9M
$9.7M
Q2 25
$-5.7M
$14.1M
Q1 25
$10.0M
$3.6M
Q4 24
$77.1M
$15.6M
Q3 24
$2.1M
$11.0M
Q2 24
$35.7M
$1.0M
Free Cash Flow
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
$13.3M
$14.4M
Q3 25
$-7.9M
$9.7M
Q2 25
$-7.3M
$14.1M
Q1 25
$9.2M
$3.6M
Q4 24
$72.2M
$15.6M
Q3 24
$-299.0K
$11.0M
Q2 24
$34.7M
$1.0M
FCF Margin
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
20.7%
19.1%
Q3 25
-12.4%
17.7%
Q2 25
-12.3%
26.8%
Q1 25
16.1%
7.7%
Q4 24
173.3%
26.4%
Q3 24
-0.6%
13.7%
Q2 24
53.3%
2.1%
Capex Intensity
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
8.7%
0.0%
Q3 25
1.6%
0.0%
Q2 25
2.7%
0.0%
Q1 25
1.4%
0.1%
Q4 24
11.9%
0.0%
Q3 24
4.9%
0.0%
Q2 24
1.5%
0.0%
Cash Conversion
FISI
FISI
PBYI
PBYI
Q1 26
Q4 25
0.94×
Q3 25
-0.34×
1.10×
Q2 25
-0.33×
2.41×
Q1 25
0.59×
1.21×
Q4 24
Q3 24
0.16×
0.54×
Q2 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FISI
FISI

Net Interest Income$52.0M83%
Noninterest Income$10.7M17%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons